Multifaceted updates concerning healthcare giant Henry Schein (HSIC) have been highlighted. UBS AM, a sub-component of UBS Asset Management Americas LLC, has downsized its stake in the company. Moreover, KKR has recently invested in Henry Schein. Notably, amidst an executive reshuffle, the company reveals its plan to magnify a $750 Million Buyback scheme. Additionally, the brokers have predicted a price target of $76.67 for Henry Schein, Inc. This news comes as the stock price is experiencing some volatility.
The company has announced the expansion of SolutionsHub in collaboration with Colaborate that could be a game changer. Despite the Q2 earnings missing the mark, the consequent revenue aligns with the expectations. Furthermore, the financial results for Q1 2025 were below estimated values, which led to some decline in the HSIC shares. However, despite this, several investment firms are seen augmenting their stakes in Henry Schein.
The announcement of the retirement of the company's CEO after transforming the company from $225M to $13B Healthcare powerhouse and a possible leadership transition has been reported. Furthermore, a strategic investment by KKR, board changes and unveiling preliminary unaudited financial results and 2025 financial guidance were reported.
Henry Schein HSIC News Analytics from Mon, 18 Nov 2024 08:00:00 GMT to Sat, 20 Sep 2025 20:38:25 GMT - Rating 3 - Innovation 2 - Information 8 - Rumor -5
